Literature DB >> 29152446

SGK1 (glucose transport), dishevelled2 (wnt signaling), LC3/p62 (autophagy) and p53 (apoptosis) proteins are unaltered in Lafora disease.

Peixiang Wang1, Lori Israelian1,2, Yunlin Xue1, Siyuan Song3, Liliana Attisano3, Berge A Minassian1,2,4.   

Abstract

Glycogen forms through the concerted actions of glycogen synthase (GS) which elongates glycogen strands, and glycogen branching enzyme (GBE). Lafora disease (LD) is a fatal neurodegenerative epilepsy that results from neuronal accumulation of hyperphosphorylated glycogen with excessively long strands (called polyglucosans). There is no GBE deficiency in LD. Instead, the disease is caused by loss-of-function mutations in the EPM2A or EPM2B genes, encoding, respectively, a phosphatase, laforin, and an E3 ubiquiting ligase, malin. A number of experimentally derived hypotheses have been published to explain LD, including: The SGK1 hypothesis - Phosphorylated SGK1 (pSGK1) raises cellular glucose uptake and levels, which would activate GS. Based on observing increased pSGK1 in LD mice it was proposed that raised pSGK1 leads to polyglucosan generation through GS hyperactivation. The Dishevelled2 hypothesis - Downregulating malin in cell culture was reported to increase levels of dishevelled2, which through the wnt/glycogen synthase kinase-3 pathway would likewise overactivate GS. The Autophagic defect hypothesis - Polyglucosans may be natural byproducts of normal glycogen metabolism. LD mice were reported to be autophagy-defective. LD would arise from failed autophagy leading to failed polyglucosan clearance. Finally, the p53 hypothesis - laforin and malin were reported to downregulate p53, their absence leading to increased p53, which would activate apoptosis, leading to the neurodegeneration of LD. In the present work we repeat key experiments that underlie these four hypotheses. We are unable to confirm increased pSGK1, dishevelled2, or p53 in LD mice, nor the reported autophagic defects. Our work does not support the above hypotheses in understanding this unique and severe form of epilepsy.

Entities:  

Keywords:  Lafora Disease; Wnt pathway; apoptosis; autophagy; glucose transport; polyglucosan

Year:  2016        PMID: 29152446      PMCID: PMC5693254     

Source DB:  PubMed          Journal:  All Results J Biol        ISSN: 2172-4784


  25 in total

1.  Glycogen hyperphosphorylation underlies lafora body formation.

Authors:  Julie Turnbull; Peixiang Wang; Jean-Marie Girard; Alessandra Ruggieri; Tony J Wang; Arman G Draginov; Alexander P Kameka; Nela Pencea; Xiaochu Zhao; Cameron A Ackerley; Berge A Minassian
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

2.  Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease.

Authors:  Jordi Duran; Agnès Gruart; Mar García-Rocha; José M Delgado-García; Joan J Guinovart
Journal:  Hum Mol Genet       Date:  2014-01-22       Impact factor: 6.150

3.  Phosphate incorporation during glycogen synthesis and Lafora disease.

Authors:  Vincent S Tagliabracci; Christian Heiss; Chandra Karthik; Christopher J Contreras; John Glushka; Mayumi Ishihara; Parastoo Azadi; Thomas D Hurley; Anna A DePaoli-Roach; Peter J Roach
Journal:  Cell Metab       Date:  2011-03-02       Impact factor: 27.287

4.  Lafora disease proteins laforin and malin negatively regulate the HIPK2-p53 cell death pathway.

Authors:  Mamta Upadhyay; Smriti Gupta; Pratibha Bhadauriya; Subramaniam Ganesh
Journal:  Biochem Biophys Res Commun       Date:  2015-06-21       Impact factor: 3.575

5.  Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease.

Authors:  Rajat Puri; Toshimitsu Suzuki; Kazuhiro Yamakawa; Subramaniam Ganesh
Journal:  Hum Mol Genet       Date:  2011-09-30       Impact factor: 6.150

6.  Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG).

Authors:  Carolyn A Worby; Matthew S Gentry; Jack E Dixon
Journal:  J Biol Chem       Date:  2007-12-10       Impact factor: 5.157

7.  Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.

Authors:  Jaiprakash Sharma; Diptendu Mukherjee; Sudheendra N R Rao; Soumya Iyengar; Susarla Krishna Shankar; Parthasarathy Satishchandra; Nihar Ranjan Jana
Journal:  J Biol Chem       Date:  2013-02-13       Impact factor: 5.157

8.  Hyperphosphorylation of glucosyl C6 carbons and altered structure of glycogen in the neurodegenerative epilepsy Lafora disease.

Authors:  Felix Nitschke; Peixiang Wang; Peter Schmieder; Jean-Marie Girard; Donald E Awrey; Tony Wang; Johan Israelian; XiaoChu Zhao; Julie Turnbull; Matthias Heydenreich; Erich Kleinpeter; Martin Steup; Berge A Minassian
Journal:  Cell Metab       Date:  2013-05-07       Impact factor: 27.287

9.  Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo.

Authors:  Vincent S Tagliabracci; Julie Turnbull; Wei Wang; Jean-Marie Girard; Xiaochu Zhao; Alexander V Skurat; Antonio V Delgado-Escueta; Berge A Minassian; Anna A Depaoli-Roach; Peter J Roach
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

10.  Activation of serum/glucocorticoid-induced kinase 1 (SGK1) underlies increased glycogen levels, mTOR activation, and autophagy defects in Lafora disease.

Authors:  Pankaj Kumar Singh; Sweta Singh; Subramaniam Ganesh
Journal:  Mol Biol Cell       Date:  2013-10-16       Impact factor: 4.138

View more
  4 in total

Review 1.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

Review 2.  Brain Glycogen Structure and Its Associated Proteins: Past, Present and Future.

Authors:  M Kathryn Brewer; Matthew S Gentry
Journal:  Adv Neurobiol       Date:  2019

3.  Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.

Authors:  Felix Nitschke; Mitchell A Sullivan; Peixiang Wang; Xiaochu Zhao; Erin E Chown; Ami M Perri; Lori Israelian; Lucia Juana-López; Paola Bovolenta; Santiago Rodríguez de Córdoba; Martin Steup; Berge A Minassian
Journal:  EMBO Mol Med       Date:  2017-07       Impact factor: 12.137

Review 4.  Lafora disease: Current biology and therapeutic approaches.

Authors:  S Mitra; E Gumusgoz; B A Minassian
Journal:  Rev Neurol (Paris)       Date:  2021-07-21       Impact factor: 4.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.